Stockscreener 앱 받기
56.93
1.28%
0.72
전일 마감가:
$56.21
열려 있는:
$56.03
하루 거래량:
2.69M
Relative Volume:
0.91
시가총액:
$25.35B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
29.82
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
-0.40%
1개월 성능:
-6.04%
6개월 성능:
+17.87%
1년 성능:
+57.53%
1일 변동 폭
$55.72
$57.08
1주일 범위
$55.13
$57.25
52주 변동 폭
$35.23
$64.38
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
56.93 | 25.35B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan
Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa
Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK
Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan
Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma PLC $RPRX Shares Sold by Corient Private Wealth LP - MarketBeat
Could Royalty Pharma’s (NASDAQ:RPRX) Story Be Changing Fast? - kalkinemedia.com
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat
Tidal Investments LLC Has $6.63 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
California State Teachers Retirement System Increases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com India
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com UK
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma (RPRX) Stock Forecast and Price Target 2026 - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Urist Marshall | Officer |
Oct 05 '26 |
Proposed Sale |
57.10 |
4,126 |
235,595 |
0 |
| Urist Marshall | Officer |
Sep 28 '26 |
Proposed Sale |
57.88 |
4,126 |
238,813 |
0 |
| Urist Marshall | EVP, Research & Investments |
Sep 28 '26 |
Sale |
57.88 |
4,126 |
238,813 |
4,126 |
| Hite Christopher | EVP & Chairman, Partnering |
Sep 22 '26 |
Sale |
58.53 |
100,000 |
5,853,095 |
270,401 |
| SCH Investment Partners LLC | Officer |
Sep 22 '26 |
Proposed Sale |
58.47 |
100,000 |
5,846,972 |
0 |
| Hite Christopher | EVP & Chairman, Partnering |
Aug 18 '26 |
Sale |
59.97 |
100,000 |
5,997,250 |
370,401 |
| SCH Investment Partners LLC | Officer |
Aug 18 '26 |
Proposed Sale |
60.12 |
100,000 |
6,012,000 |
0 |
| Coyne Terrance P. | EVP & CFO |
Aug 13 '26 |
Sale |
58.68 |
11,002 |
645,551 |
0 |
| Terrance Coyne | Officer |
Aug 13 '26 |
Proposed Sale |
58.56 |
11,002 |
644,277 |
0 |
| Errol B. De Souza | Former Affiliate |
Aug 12 '26 |
Proposed Sale |
57.79 |
206,352 |
11,925,082 |
0 |
3.60%
자본화:
|
볼륨(24시간):